Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.
Financial Results:
Aurobindo Pharma Ltd reported Revenues for Q1FY25 of ₹7,567.00 Crores up from ₹6,851.00 Crore year on year, a rise of 10.45%.
Total Expenses for Q1FY25 of ₹6,464.00 Crores up from ₹6,086.00 Crores year on year, a rise of 6.21%.
Consolidated Net Profit of ₹918.00 Crores up 61.05% from ₹570.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹15.69, up 61.09% from ₹9.74 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.